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ABSTRACT
Introduction: In the prospective, open-label,
non-interventional, multicenter RESPONSIfVE
study, the effectiveness, response rates and
tolerability of ivabradine with or without beta
blocker (BB) were evaluated in patients with
chronic stable angina pectoris (AP) in daily
clinical practice.
Methods: In patients with AP, ivabradine was
given twice daily in flexible doses for 4 months.
Resting heart rate (HR), number of angina
attacks, short-acting nitrate use, severity of
symptoms [by Canadian Cardiovascular
Society (CCS) score] and tolerability with or
without existing BB therapy were documented
and analyzed using descriptive statistical
methods.
Results: In total, 1250 patients with AP (mean
age 66.0 ± 10.9 years, 59.6% male, 31.9%
previous myocardial infarction) and an
indication for ivabradine were included.
Sixty-five percent of all patients received BB.
Further concomitant standard medication
included aspirin (74.2%), statins (69.3%),
angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers (84.2%),
diuretics (40.0%), long-acting nitrates (15.7%),
and calcium antagonists (21.4%). After
4 months of ivabradine treatment (mean daily
dose 11.0 ± 2.7 mg), mean HR was reduced
from 82.4 ± 11.8 beats per minute (bpm) to
67.1 ± 8.4 bpm. The average number of angina
attacks/week decreased from 1.2 ± 1.9 to
0.1 ± 0.6 and the average use of short-acting
nitrates/week from 1.5 ± 2.8 units to
0.2 ± 1.0 units. CCS classification of patients
improved from 76% classified in CCS grades II
or III and 24% in CCS grade I to 66% classified
in CCS grade I and only 35% remaining in CCS
grades II or III at study end. Response rate to
ivabradine (defined as HR\70 bpm or HR
reduction C10 bpm) reached 87%. HR
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reduction, symptomatic improvement and
response rates were comparable in patients
with or without BB. Adverse drug reactions
were reported for 2.2% of patients.
Conclusion: In this prospective study over a
four-month period in clinical practice,
ivabradine effectively reduced HR, angina
attacks, and nitrate consumption in patients
with AP with or without concomitant BB
therapy. Ivabradine improved CCS scores and
achieved a high treatment response rate with
good general tolerability.
Funding: Servier.
Trial registration: Controlled-trials.com iden-
tifier, ISRCTN73861224.
Keywords: Angina attacks; Beta blocker;
Cardiology; CCS grade; Heart rate reduction;
Ivabradine; Nitrate consumption; Stable angina
pectoris; Symptom improvement
INTRODUCTION
High heart rate (HR) induces myocardial
ischemia and thereby triggers symptoms of
angina pectoris (AP) in the presence of
coronary stenoses [1–3]. Elevated HR is also
associated with increased cardiovascular and
total mortality in patients with coronary artery
disease (CAD), after myocardial infarction (MI),
with chronic heart failure (CHF), and also in the
general population without obvious
cardiovascular disease [4–9]. Reducing HR has
therefore become an important therapeutic
strategy in the treatment of patients with
cardiovascular disease, also being reflected in
international guidelines [10–12].
While HR reduction with beta blockers,
which are most commonly used for that
purpose, or ivabradine, which is selectively
blocking the ‘‘funny’’ current (If) channel in the
pacemaker cells of the sinoatrial node [13], have
both been shown to improve cardiovascular
mortality and morbidity in patients with CHF
[12], rather mixed results were found in patients
with stable CAD. According to a couple of new
analyses, an improvement of prognosis with beta
blocker in stable CAD seems to be strictly
restricted to a population with recent MI
[14–16]. On the other hand, a subgroup
analysis of the BEAUTIFUL trial
(ClinicalTrials.gov identifier: NCT00143507)
revealed that ivabradine in addition to beta
blocker and other guideline recommended
therapies improved coronary outcomes in
patients with CAD with left ventricular (LV)
systolic dysfunction and limiting AP [17, 18],
while neutral results were obtained for
ivabradine in the recent SIGNIFY trial
(ClinicalTrials.gov identifier: NCT02446990) in
patients with stable CAD with preserved LV
function and no signs of heart failure [19]. In
SIGNIFY, a small but statistically significant
increase in the occurrence of the primary
endpoint was seen for ivabradine compared to
placebo in the subgroup of patients with limiting
angina [Canadian Cardiovascular Society
(CCS) C2]. However, it should be noted that
considerably higher ivabradine doses than
currently approved by health authorities have
been used in that trial.
Given the very low mortality rates with
contemporary guideline recommended
medications in stable CAD [19, 20], the main
focus of therapy shifts to improvement of
residual angina symptoms, exercise capacity
and therefore quality of life (QoL) in these
patients. To achieve these goals, recent
guidelines for the treatment of stable CAD
recommend reducing the resting HR of patients
with CAD to between 55 and 60 beats per
minute (bpm) [10, 11]. In clinical practice, HR
reduction with beta blocker alone is not always
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sufficient and many patients remain
symptomatic [21, 22]. In addition, due to their
broad mode of action and resulting side effects,
up-titration of beta blockers often remains a
difficult barrier in daily routine [21]. Current
European Society of Cardiology (ESC) guidelines
recommend ivabradine not only as an
alternative anti-anginal agent to beta blockers,
but especially emphasize the role of combining
beta blockers and ivabradine for more effectively
reducing HR and improving AP symptoms [11].
The efficacy and safety of ivabradine in
symptomatic AP therapy has been shown in
controlled trials without concomitant
beta-blocker use [23, 24]. Moreover, the
ASSOCIATE study (ClinicalTrials.gov identifier:
NCT00202566) including over 800 patients with
stable AP, proved that combining ivabradine and
beta blocker was effective and safe under
controlled conditions [25]. This was also
demonstrated in the setting of everyday clinical
practice by two large observational studies in
patients with and without beta-blocker treatment
[26–28], resulting in reduction of angina attacks
and need for short-acting nitrates. CCS class
distribution and QoL also improved,
accompanied by good general tolerability.
We designed the RESPONSIfVE (Evaluation of
effectiveness and therapeutic response to
ivabradine in daily practical use for chronic
stable angina patients) study to further assess the
symptomatic effectiveness, treatment response,
and tolerability of ivabradine in one large cohort
ofpatientswithstableAPwithandwithoutexisting
beta-blocker therapy in daily clinical practice.
METHODS
Patients with stable AP requiring further
anti-anginal treatment and fulfilling criteria
for ivabradine therapy according to the
approved indication and ESC guideline
recommendations [11] were included in this
non-interventional study by general
practitioners and internists in an outpatient
setting. In detail these were symptomatic
patients with coronary heart disease and
normal sinus rhythmus, who were either
unable to tolerate or had a contraindication to
beta blockers, or were not adequately controlled
with an optimal (meaning maximally tolerated)
beta-blocker dose (HR[60 bpm at the time of
the study). Symptomatic patients with and
without concomitant beta-blocker therapy
could therefore be included into the study.
Exclusion criteria were defined by explicit
contraindications for ivabradine treatment
according to approved drug label. There were
three scheduled visits, one at baseline (visit 1), a
control visit after 4 weeks (visit 2), and the final
examination after 4 months (visit 3). All data
was documented using a standardized case
report form (CRF).
The procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study. Ethical approval was granted by
the independent ethics commission in Freiburg/
Germany (FEKI). This trial is registered at
controlled-trials.com with registration number
ISRCTN73861224. Demographic and
disease-specific medical history data,
information about concomitant diseases, other
medical therapies and reasons for initiating
ivabradine treatment were recorded at baseline
visit. Patients were treated with ivabradine in
flexible doses over a 4-month period. The
recommended starting dose was 5 mg twice
daily (2.5 mg twice daily in elderly patients
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aged C75 years). If necessary, the dose could be
adjusted at visit 2 to a maximal dose of 7.5 mg
twice daily or a lower dose of 2.5 mg twice daily
in case of pronounced HR reduction\50 bpm.
Stable AP was clinically documented at each
visit by recording HR, weekly angina symptoms,
weekly nitrate use, and CCS class. Other cardiac
parameters assessed at baseline and/or during
the course of the study were, e.g., NYHA class,
LV dysfunction (LVD), history of MI,
revascularization therapies like percutaneous
coronary intervention (PCI) or coronary artery
bypass grafting (CABG), and blood pressure. At
visit 3, all changes in concomitant medications
were evaluated. To assess the overall response
rate of patients to ivabradine, treatment
response was defined as achieving a
HR\70 bpm and/or an absolute HR reduction
of C10 bpm at study end (visit 3). In addition, a
final evaluation of the overall effectiveness and
tolerability of ivabradine therapy was made
using a physician’s assessment scale with
categories ‘‘very good’’, ‘‘good’’, ‘‘moderate’’,
and ‘‘poor’’.
The main focus of this study was to evaluate
the symptomatic outcome of ivabradine-treated
patients with and without concomitant
beta-blocker therapy. For assessment of
beta-blocker treatment status, patients were
further divided into three subgroups according
to the beta-blocker dose at baseline as a
percentage (\50%, 50–99%, C100%) of the
defined maximal doses. Additional subgroups
were specified according to gender, age
(\/C75 years), resting HR (\/C75 bpm), CCS
class (I–IV), patients with or without MI, PCI
or LVD, and patients on monotherapy or
add-on treatment with ivabradine at baseline.
All adverse drug reactions (ADR) occurring
during the study period had to be documented
and assessed by the physician on a specific ADR
reporting form at each patient visit. ADR were
coded in accordance with the Medical
Dictionary for Regulatory Activities (MedDRA)
version 17.0.
A strictly descriptive statistical analysis of the
results was performed due to the
non-interventional design of the study. Data
are presented as mean values ± standard
deviations (SD) for continuous variables and
numbers of patients and/or percentages for
categorical variables. Analysis of effectiveness
data was performed with data imputation
according to the last value carried forward
(LVCF) method. Wilcoxon’s signed-rank test
and Chi-square test were applied for
assessment of changes between baseline and
follow-up visits. Corresponding P values should
be interpreted descriptively. All study data were
evaluated by an independent statistical institute
(ANFOMED GmbH, Mo¨hrendorf, Germany). All
statistical analyses have been performed by
means of the SAS software system (version
9.4 for Microsoft Windows 7TM; SAS Institute
Inc., Cary, NC, USA).
RESULTS
Baseline
A total of 1250 patients with chronic stable AP
(intention to treat population) were enrolled in
this non-interventional study in 338 centers in
Germany. Data of 1247 patients (99.8%) were
available for all three visits. The mean study
duration was 4.05 months. The mean age of the
cohort was 66.0 ± 10.9 years (22.9% C 75 years),
59.6% of the patients were male. 31.9% of the
total study cohort had a history of MI, 46.8% and
11.1% underwent PCI or CABG, respectively.
34.5% of patients had LVD, mean LV ejection
fraction (LVEF) was 47.0% ± 11.9%. Conduction
disorders were present in 18.1% of patients. Atrial
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fibrillation, mainly paroxysmal, was diagnosed
in 11.9% of the study population. The most
common concomitant diseases/risk factors were
arterial hypertension (84.2%), dyslipidemia
(62.2%), obesity (41.3%), smoking (34.5%), and
diabetes (33.2%). Cardiovascular medication at
baseline consisted of, e.g., Aspirin (74.2%),
statins (69.3%), angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers
(84.2%), diuretics (40.0%), calcium antagonists
(21.4%), and long-acting nitrates (15.7%; see
Table 1 for subgroup data).
64.7% of all patients received beta blockers.
17.9% of those patients received C100% of the
defined maximal dose, 55.6% between 50% and
99% of the maximal dose, and 26.5% less than
50% of the maximal dose (Table 2).
Ivabradine was selected as initial therapy in
34.6% of patients and in 49.6% as additional
therapy. 15.8% of patients switched to
ivabradine, most frequently from beta blocker,
and often due to intolerance/side effects
(58.9%) or insufficient efficacy (50.0%). At
study entry and last visit, mean daily dose of
ivabradine was 9.7 ± 1.8 and 11.0 ± 2.7 mg,
respectively. Initially, 86.8% of patients
received 2 9 5 mg ivabradine per day. In
62.6% of patients, the initial dose remained
constant during the study, while it was
escalated to the targeted maintenance dose of
2 9 7.5 mg per day in 22.8% of the patients.
Treatment Effects of Ivabradine
At baseline, mean HR was 82.4 ± 11.8 bpm in
all patients, and 80.6 ± 11.0 or 85.5 ± 12.3 bpm
in patients with and without beta-blocker
therapy, respectively. After 4 months of
treatment, ivabradine reduced mean HR by
15.2 bpm to 67.1 ± 8.4 bpm in the total study
cohort. The mean HR dropped by 14.5 bpm to
66.1 ± 7.9 bpm and by 16.6 bpm to
69.0 ± 8.9 bpm in patients with or without
existing beta-blocker therapy, respectively
(P\0.001; Fig. 1). During the course of the
study, the proportion of patients with
HR\70 bpm increased considerably from
12.1% to 67.5%. Due to their lower baseline
HR, patients on beta blocker more often reached
HR\70 bpm compared to those without beta
blocker (72.3% vs. 58.8%). At study end,
response rate to ivabradine treatment, defined
as HR\70 bpm or HR reduction of C10 bpm,
amounted to 87.5%. Only slightly higher
response rates were seen in patients with
concomitant beta-blocker therapy (and also
with higher doses) compared to patients
without such treatment (88.5% vs. 85.7%).
Treatment response rates were comparable
through a wide range of patient subgroups
analyzed (Fig. 2).
At baseline, the average number of angina
attacks per week was 1.2% ± 1.9. 49.0% of all
patients suffered from C1 angina attack per week.
After 4 months, ivabradine led to a decrease of the
average number of angina attacks per week to
0.1 ± 0.6 (mean difference -1.1). Percentage of
patients without weekly angina attacks increased
from 51.0% to 92.0%. No marked differences were
found for patients with or without concomitant
beta-blocker therapy, with a reduction of the
average number of angina attacks per week from
1.3 to 0.2 and 1.0 to 0.1, respectively (P\0.001;
Fig. 3a, b).
The average baseline consumption of
short-acting nitrates per week was
1.5 ± 2.8 units. After 4 months of ivabradine
therapy, average weekly consumption of
short-acting nitrates dropped to 0.2 ± 1.0 units
(mean difference -1.3 units). Percentage of
patients without weekly nitrate use increased
from 61.1% to 92.2%. Comparable results in
effect size were observed in patients with or
without existing beta-blocker therapy
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(P\0.001; Fig. 3c), with a drop in average
consumption of short-acting nitrates per week
from 1.8 to 0.2 and 1.1 to 0.2 units, respectively.
At study entry, 23.8% of patients were
classified CCS grade I, 54.0% CCS grade II,
21.5% were in CCS grade III, and 0.6% in CCS
grade IV. A pronounced shift and improvement











Age (years) 66.2 ± 10.8 65.9 ± 11.1
C70 years 324 (41%) 179 (41%)
C80 years 79 (10%) 41 (9%)
Male sex 496 (62%) 219 (50%)
Time since angina
diagnosis (months)
45.7 ± 47.5 45.4 ± 48.2
Medical history
Previous PCI 438 (55%) 146 (33%)
Previous CABG 101 (13%) 37 (8%)
Previous myocardial
infarction
294 (37%) 101 (23%)
Valvular heart disease 129 (16%) 64 (15%)
Hypertension 691 (87%) 346 (79%)
Dyslipidemia 526 (66%) 243 (56%)
Obesity 351 (44%) 160 (37%)
Diabetes mellitus 268 (34%) 141 (32%)
Peripheral artery disease 76 (10%) 45 (10%)
COPD 83 (10%) 130 (30%)
Asthma 24 (3%) 86 (20%)
Nephropathy 51 (6%) 31 (7%)
Cardiovascular medication
Beta blockers 798 (100%) 0 (0%)
ACE inhibitors 477 (60%) 216 (50%)
AT1 antagonists 217 (27%) 130 (30%)
Aldosterone receptor
antagonists
71 (9%) 19 (4%)
Calcium antagonists 155 (19%) 109 (25%)
Long-acting nitrates 140 (18%) 54 (12%)
Molsidomine 76 (10%) 39 (9%)










Diuretics 333 (42%) 163 (37%)
Aspirin 623 (78%) 296 (68%)
Clopidogrel/prasugrel/
ticagrelor
134 (17%) 51 (12%)
Statins 609 (76%) 252 (58%)
Other lipid-lowering
agents
41 (5%) 22 (5%)
Clinical ﬁndings
Heart rate (bpm) 80.6 ± 11.1 85.5 ± 12.3
Weekly number of angina
attacks
1.3 ± 1.9 1.0 ± 1.8
Weekly use of nitrates 1.8 ± 3.0 1.1 ± 2.4
Systolic blood pressure
(mm Hg)
135.7 ± 14.9 137.0 ± 16.3
Diastolic blood pressure
(mm Hg)
81.1 ± 9.3 81.5 ± 9.6
Canadian Cardiovascular Society class
Class I 167 (21%) 123 (28%)
Class II 428 (54%) 211 (48%)
Class III 175 (22%) 79 (18%)
Class IV 9 (1%) 1 (\1%)
Values are presented as patient numbers and percentages or
means ± standard deviations
ACE angiotensin-converting enzyme, AT1 angiotensin
receptor 1, bpm beats per minute, CABG coronary artery
bypass graft, COPD chronic obstructive pulmonary disease,
PCI percutaneous coronary intervention
Adv Ther (2016) 33:1550–1564 1555
in CCS grade distribution towards lower classes
was observed. At the end of follow-up, most
patients (65.6%) were classified CCS grade I,
29.9% were in CCS grade II, 4.6% in CCS grade
III, and none in CCS grade IV (P\0.001 for all
class changes; Fig. 4). While at baseline, patients
on beta blocker were more frequently in severe
CCS classes, after four months of ivabradine
therapy, no clear differences were documented
for patients with or without concomitant
beta-blocker intake. Symptomatic improvement
and CCS classification shifts were generally
comparable among the specified patient
subgroups and irrespective of a concomitant
beta-blocker therapy or the applied beta-blocker
dose (\50%, 50–99%, or C100% of maximal
dose). For all effectiveness parameters, most of
the beneficial effects associated with ivabradine
therapy were already observed in month 1 with a
further increase in month 4.
Overall, during the course of the study no
relevant changes in beta-blocker therapy or
dosage, or that of other cardiovascular and
anti-anginal medications, were documented.
Adherence to treatment with ivabradine was
quite high, with 4.4% of patients discontinuing
treatment during the study period.
Tolerability
ADR were reported for 2.2% (n = 28) of patients
(mostly bradycardia 0.4%, palpitations 0.2%,
photopsia 0.2%). Serious ADRs (SADRs)
occurred in 0.4% (n = 5) of patients, e.g.,
bradycardia and atrial fibrillation. There were
Table 2 Beta-blocker therapy of the study cohort at baseline visit
Beta blocker therapy Metoprolol Bisoprolol Nebivolol Carvedilol Othersb
Patients (n = 798) 362 (45%) 336 (42%) 57 (7%) 32 (4%) 11 (1%)
Daily dose (mg; n = 759) 95.1 ± 48.6 6.1 ± 3.2 5.0 ± 1.9 27.3 ± 15.8 –
Patient distribution by % of maximal dosea (n = 759)
\50% 121 (35%) 47 (14%) 11 (20%) 22 (73%) –
50–99% 174 (50%) 200 (61%) 40 (71%) 8 (27%) –
C100% 52 (15%) 79 (24%) 5 (9%) 0 (0%) –
Values are patient numbers and percentages or means ± standard deviations
a Deﬁned maximal doses of beta blockers: metoprolol 190 mg/day, bisoprolol and nebivolol 10 mg/day, carvedilol
100 mg/day
b Dose analysis only performed for metoprolol, bisoprolol, nebivolol and carvedilol
Fig. 1 Reduction in resting heart rate with initiation of
ivabradine in patients with stable angina with or without
beta-blocker therapy at baseline. *P\0.001 (change
between baseline and month 1 and baseline and month
4 for both subgroups). bpm beats per minute
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no SADRs resulting in MI or death. No
unexpected safety signals have been reported.
In addition, there was no relevant difference in
ADR/SADR incidence rates or their profile
between patients with or without existing
beta-blocker therapy (Table 3). Finally, the
effectiveness of ivabradine treatment was rated
by the treating physicians as ‘‘very good’’ and
‘‘good’’ for 71.3% and 26.3% of patients, and
tolerability for 76.5% and 22.4%, respectively.
Both in terms of effectiveness and tolerability
rating, no pronounced effect of concomitant
beta-blocker therapy was documented.
DISCUSSION
The main finding of our study is that the
selective If inhibitor ivabradine is effective and
safe in a broad spectrum of patients with
stable CAD with or without concomitant
beta-blocker therapy, showing consistently
high treatment response rates regarding HR
reduction. To our knowledge, the present
study is the first to analyze response to
ivabradine treatment in a wide range of
subgroups in clinical practice.
For the use of ivabradine without existing
beta-blocker therapy, symptomatic effects in
our study are in line with results of various
clinical trials [23, 24]. In the INITIATIVE study,
an equivalent symptomatic efficacy of
ivabradine and the beta-blocker atenolol was
proven [23]. Our findings mirror as well the
Fig. 2 Treatment response in various subgroups after
4 months of ivabradine therapy. ‘‘Response’’ deﬁned as
achieving a heart rate\70 bpm or a heart rate reduction
of C10 bpm after 4 months. BB beta blocker, bpm beats
per minute, CCS Canadian Cardiovascular Society, LVD
left ventricular dysfunction,MI myocardial infarction, PCI
percutaneous coronary intervention
Fig. 3 Change in angina frequency (a), mean number of
angina attacks (b) and frequency of nitrate uses (c) per
week in patients with or without beta-blocker therapy at
baseline. *P\0.001 (change between baseline and month
1 and/or baseline and month 4 for both subgroups)
c
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symptomatic effectiveness and safety profile of
ivabradine in combination with beta blocker
previously demonstrated in the ASSOCIATE
trial [25], and in two non-interventional
studies [27, 28]. Taken together, all these
previous studies concluded that ivabradine as
either antianginal monotherapy or in
combination with beta blocker was effective
and well tolerated, not only in selected patient
populations but also in daily clinical practice.
In our study, a typical mixed population of
patients with stable CAD in the outpatient
setting with angina symptoms and including
participants with or without LVD was assessed.
To further strengthen the available data on HR
reduction, improvement of angina symptoms
and tolerability with ivabradine as
monotherapy or combined with beta blocker,
we decided to design a non-interventional
study as this might result in a more realistic
picture of everyday use of the drug in, e.g.,
elderly patients with comorbidities, which are
usually not sufficiently represented in
controlled clinical trials.
Adding ivabradine to the treatment plan led
to a further substantial reduction in resting HR
by 15.2 bpm without relevant differences
between patients treated with beta blocker or
not. Taking into account a slightly lower
baseline HR in the two-thirds of patients on
beta blockers compared to patients without beta
blocker (80.6 vs. 85.5 bpm), 4 months of
ivabradine therapy allowed for a better HR
control in both subgroups with only small
between-group variation. A similar observation
was made in terms of treatment response
(HR\70 bpm or HR reduction of C10 bpm at
month 4) with an only slightly higher success
rate for patients treated with both ivabradine
and beta blocker. These results are in good
agreement with findings from a large
observational study, where a comparable
reduction of HR in participants with or
without concomitant beta-blocker therapy was
Fig. 4 Change in severity of angina from baseline to 4
months, according to CCS class, in patients with or
without beta-blocker therapy at baseline. *P\0.001
(change between baseline and month 4 for both sub-
groups). CCS Canadian Cardiovascular Society
Table 3 Most frequently reported adverse drug reactions,
according to beta-blocker therapy, classiﬁed using












18 (2.3%) 10 (2.3%)
Bradycardia 3 (0.4%) 2 (0.5%)
Dizziness/syncope 2 (0.3%) 1 (0.2%)
Palpitations 2 (0.3%) 1 (0.2%)
Photopsia
(phosphenes)
2 (0.3%) 1 (0.2%)
Atrial ﬁbrillation 1 (0.1%) 1 (0.2%)
Values are patient numbers and percentages
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found [26], although the proportion of patients
treated with beta blockers was considerably
lower in that cohort. HR response rates and
symptomatic effects were comparable across all
analyzed subgroups.
Correspondingly, after 4 months of
ivabradine therapy both the weekly number of
angina attacks and consumption of short-acting
nitrates declined substantially. At study end,
approximately 90% of patients were free of
angina symptoms and without need to use
short-acting nitrates. These observations were
accompanied by a pronounced shift in CCS
grade distribution towards lower classes. Despite
beta-blocker patients being more symptomatic
at baseline, probably reflecting the fact that
sicker patients were more likely to receive beta
blockers, the treatment effect of ivabradine was
consistent and comparable in patients with or
without beta-blocker therapy after 4 months. At
the end of follow-up, the percentage of patients
in CCS grade I almost tripled irrespective of
concomitant beta-blocker therapy. Although
QoL was not specifically addressed in our
study, a strong correlation between CCS
classification and health-related QoL
questionnaires like the EQ-5D is well
established [29]. Given this association, an
additional benefit of ivabradine therapy on
QoL has been demonstrated in patients on
beta blockers in the ADDITIONS study
(Controlled-trials.com identifier: ISRCTN532
33058) [28] and can also be assumed for the
present study cohort on basis of the
improvement in CCS grade distribution after
4 months of treatment.
Overall, the magnitude of HR reduction,
decline of angina symptoms, nitrate
consumption, and improvement in CCS class
with ivabradine over 4 months was comparable
to previous observational studies [26, 28].
Moreover, a small subgroup analysis of an
observational study allowing a comparison of
ivabradine patients with and without existing
beta-blocker therapy revealed no clear influence
of beta-blocker therapy on the effectiveness or
tolerability of ivabradine in ‘‘real-life’’ patients
with stable AP [27], emphasizing the findings of
our study. In addition, no relevant differences
between HR reduction or its effects on angina
symptoms, nitrate use or CCS class
improvement were revealed between patients
taking\50%, 50–99%, or 100% of the maximal
beta-blocker dose. In support of our results,
reaching maximal approved beta-blocker doses
failed to show additional positive effects in
combination with ivabradine in patients with
stable AP [30] and CHF [31] compared to lower
beta-blocker doses.
In our unselected patient population the
effect on HR was more pronounced than in the
BEAUTIFUL or SHIFT study (Controlled-
trials.com identifier: ISRCTN70429960)
[17, 32], which might be explained by the
higher baseline HR despite beta-blocker
treatment in the majority of patients. Greater
HR reduction with ivabradine was in good
agreement to that seen in ‘‘real-life’’ patients in
other non-interventional studies [26, 28] and
can be explained with the pharmacological
properties of ivabradine, for which the
magnitude of the HR-reducing effect is
considered ‘‘use-dependent’’ and strongly
correlates to baseline HR [13, 33]. High HR at
baseline may also reflect physicians’ perception
that ivabradine is especially indicated and
useful in patients with considerably high
resting HR. The treatment decision should
rather be in line with results from studies like
BEAUTIFUL [17, 18] or SHIFT [32], in which
patients with an initial HR C70 bpm showed
pronounced benefit on certain outcome
endpoints. The mean HR achieved in our
study was 67.1 bpm, which is still above the
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resting HR (\60 bpm) recommended in
international guidelines for patients with
stable CAD [10, 11]. This might also be
explained by the relatively low dose of
ivabradine with a mean daily dose of 11.0 mg
at last visit, compared to the approved
maintenance dose of 15 mg/day. Up-titration
to the full dose might have further increased the
therapeutic effects of ivabradine.
In good agreement with recent registries and
surveys [21, 22], beta blockers in our study were
mostly not at maximal dose due to either side
effects (mostly tiredness, fatigue, erectile
dysfunction, hypotension) or existing
comorbidities (chronic obstructive pulmonary
disease, asthma, conduction disturbances,
psoriasis). As up-titration was not successful in
these symptomatic patients with persistently
elevated HR due to the mentioned obstacles,
alternative anti-anginal treatment needed to be
considered. The current results show that
combining beta blocker with ivabradine
appears to be a valuable option in patients
who do not tolerate high-dose beta-blocker
therapy or those with insufficient reduction of
HR or with persisting angina symptoms.
Moreover, there are convincing study data
showing that adding ivabradine to beta
blockers seems to be more effective than
up-titration of beta blockers in patients with
stable AP [34].
Combined ivabradine and beta-blocker
therapy was well tolerated without any relevant
differences compared to patients receiving
ivabradine without beta blocker. The rate of
ADR is in good agreement with results from
other non-interventional studies [26, 28, 31], but
is lower than in randomized, controlled trials
[17, 32], which might also be explained by
higher HR at inclusion in the present study. In
particular, the SADR rate was low (0.4%), and
altogether only 0.4% of the patients experienced
bradycardia. Of special interest is the sharp
contrast to the recent findings of the large
randomized, controlled SIGNIFY study, where
ivabradine was applied ‘‘off-label’’ in a higher
than authorized starting (2 9 7.5 mg per day)
and maintenance dose (up to 2 9 10 mg per
day), resulting in excess bradycardia and a small
but significant increase of primary endpoint
events in a subgroup of patients with limiting
angina [19]. Concomitant therapy with the
HR-lowering calcium antagonists verapamil and
diltiazem (4% of patients in the angina
subgroup) was considered as another important
risk factor in this trial. As a result of a thorough
reviewing process of the SIGNIFY data by the
European Medicines Agency (EMA), combining
ivabradine with verapamil or diltiazem is now
contraindicated. Although 8% of our patients
were on one of these drugs, no apparent safety
signals could be detected with ivabradine given
within the limits of its usual and approved
dosing regimen.
Taken together, the results from
RESPONSIfVE add to the current evidence
showing a marked symptomatic improvement
in patients with stable AP in everyday practice
with ivabradine given either as sole antianginal
therapy or in combination with beta blocker.
The effect size and tolerability were
independent of concomitant beta-blocker
therapy. It should be noted in this context
that apart from HR-dependent effects there is
also good evidence for pleiotropic actions of
ivabradine, which are independent from HR
reduction. Mechanisms for example involve
attenuated formation of reactive oxygen
species in cardiomyocyte mitochondria
[35, 36]. Such results distinguish ivabradine
from other currently used anti-anginal
medication, like beta blockers, calcium
antagonists or nitrates and may have
contributed to the effects seen in RESPONSIfVE.
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Study Limitations
One important limitation of this trial is its
open-label, observational, non-interventional
design without placebo group, which may lead
to an overestimation of treatment effects. The
efficacy of ivabradine with or without beta
blocker use has been consistently proven in
controlled clinical trials with patients with
chronic stable AP [23–25]. Moreover, our open
study design allows evaluation of treatment
effects under conditions of routine clinical
practice, while in controlled studies strict
inclusion criteria usually restrict access of
broader patient populations with multiple
comorbidities and risk factors. Another
limitation is the short study duration of 4
months, which is nevertheless sufficient to
evaluate symptom reduction in patients with
AP, as demonstrated in other controlled and
‘‘real-life’’ studies [25, 26, 28]. High resting HR at
baseline can also lead to an overestimation of
the treatment benefit, as ivabradine effects are
more pronounced in patients with high HR due
to its use-dependent mechanism of action
[13, 33]. But with less than a quarter of
patients being up-titrated to the target dose of
ivabradine beneficial effects may also be
undervalued.
Due to the non-interventional design, an
underestimation of potentially ivabradine-
related adverse events cannot be fully
excluded, as they were assessed only in the
form of an open evaluation at each visit. But
taking into account favorable safety results from
clinical trials, when used according to the
approved dosing regimen, ivabradine alone or
in combination with beta-blocker therapy and
other frequently prescribed drugs appears to be
well tolerated in patients with chronic
stable AP.
CONCLUSIONS
In this prospective study over a four-month
period in daily clinical practice, ivabradine
effectively reduced HR, angina symptoms and
nitrate consumption in a cohort of patients
with chronic stable AP with or without existing
beta-blocker therapy. Moreover, ivabradine
improved CCS symptom scores and achieved
high treatment response rates in this mixed
population with cardiovascular comorbidities.
Treatment effects of ivabradine were
comparable in patients with or without
beta-blocker use and in various other
subgroups. Ivabradine therapy was associated
with a good general tolerability profile. In line
with current guideline recommendations, the
results of our study emphasize the potential for
better HR and symptom control with ivabradine
in patients with chronic stable AP, irrespective
of concomitant beta-blocker treatment.
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